The document referenced is an expert consensus produced through a national Delphi process by the Immunodeficiency Group of the Spanish Society of Immunology. Its stated purpose is to provide recommendations for the prevention and management of adverse reactions associated with immunoglobulin therapy. The target clinical area combines therapeutic use of immunoglobulin products and the safety considerations that arise when treating patients with immune deficits.
The publicly visible excerpt provided for this task contained only Frontiers in Immunology web navigation and journal metadata. The excerpt did not include the article body, tables, figures, or the consensus statements themselves. The title and journal citation were available and form the basis for this summary and editorial rewrite.
The consensus is explicitly focused on two major patient groups: primary immunodeficiencies (PID) and secondary immunodeficiencies (SID). These broad categories reflect patients who receive immunoglobulin replacement or immunomodulatory immunoglobulin for a variety of indications and who may therefore be at risk of infusion-related or post-infusion adverse events.
The provided source excerpt does not describe how PID and SID populations were defined for the Delphi panel, nor does it report whether recommendations differ between these groups, by age, by route of administration (intravenous vs subcutaneous), or by specific comorbidities.
Based on the article title, the consensus addresses two complementary clinical tasks:
Because the full text was not available in the supplied content, the specific preventive interventions recommended, management algorithms, graded strength of recommendations, or any suggested clinical pathways are not reported here.
What is available from the supplied material:
What is not available in the provided excerpt and therefore cannot be restated or summarized:
When primary article content is unavailable, stating these absences is essential to avoid implying unreported specifics.
Given the stated aim, this national Delphi consensus would be expected to serve clinicians involved in the prescription and administration of immunoglobulin products, including immunologists, infectious disease specialists, hematologists, primary care physicians, nursing staff, and pharmacists. Potential uses—consistent with the title—would include:
However, without the article body, concrete examples, algorithms, or practice points that clinicians could implement cannot be provided here.
The principal limitation of this summary is that the provided source excerpt did not include the consensus content. As a result, no specific recommendations, evidence levels, or panel findings can be reported. To evaluate the strength, applicability, and details of the guidance, readers should consult the complete article.
Next steps for readers interested in applying the consensus in practice:
The citation available identifies this work as published in Frontiers in Immunology and authored by the Immunodeficiency Group of the Spanish Society of Immunology. The full consensus recommendations, methods, and supporting materials are available in the complete article on the journal website. The provided excerpt did not include the article text; therefore readers should retrieve the full publication from Frontiers in Immunology to obtain actionable clinical recommendations and the detailed Delphi results.
Summary
This resource is a society-driven national Delphi consensus focused on preventing and managing adverse reactions to immunoglobulin therapy in patients with primary and secondary immunodeficiencies. The provided source content for this rewrite consisted of site navigation and metadata only; the substantive recommendations and methodological details were not reported in the excerpt. For clinical adoption, consult the full published article for the specific consensus statements, their rationale, and implementation guidance.